Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Violacein biosynthesis protein VioB is a critical enzyme in the biosynthetic pathway of violacein, a bis-indole pigment produced by various bacteria, most notably Chromobacterium violaceum [1, 2]. As a heme-dependent oxidase, VioB catalyzes the dimerization of two indole-3-pyruvic acid (IPA) imine molecules, a key step in constructing the complex pyrrolidone-containing scaffold of violacein [2, 31]. This enzyme is of significant interest in biotechnology and medicine due to the potent biological activities of its product, violacein, which exhibits antibacterial, antifungal, and antitumoral properties [3, 35]. VioB is considered a therapeutic target for anti-virulence strategies aimed at reducing the toxicity of C. violaceum, an opportunistic human pathogen, as its inhibition leads to the depletion of violacein and a subsequent decrease in bacterial virulence [5]. Additionally, VioB is a primary focus for metabolic engineering efforts to enhance the microbial production of violacein for pharmaceutical applications [2, 35].
Catalyzes the oxidative coupling and dimerization of two molecules of indole-3-pyruvic acid (IPA) imine to form a precursor of violacein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Violacein biosynthesis protein VioB (VioB).